R&D News | pharmaphorum

Tuesday 16 June 2026

News

News

US vulnerable to China's API dominance, says report

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

News

GSK pumps £45m into antimicrobial resistance projects

GSK pumps £45m into antimicrobial resistance projects

GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.

News

Roche extols 'unprecedented' result with breast cancer drug

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

EBAI schematic

New guidance covers AI-based biomarkers for cancer care

ESMO guidance on the validation and clinical use of AI-based biomarkers in oncology aims to strike a balance between caution and over-reliance.

News

Halda Therapeutics' president and chief executive, Christian Schade

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.

News

red blood cells

BMS, J&J give up on milvexian for acute coronary syndrome

BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.